Achieve Life Sciences Inc. reported its financial results for the quarter ended March 31, 2025, revealing a total net loss of $12.8 million. The company's cash, cash equivalents, and marketable securities stood at $23.2 million as of the same date. Total operating expenses for the quarter amounted to $12.9 million. The company continues to focus on the development and potential commercialization of its smoking cessation treatment, cytisinicline, with no significant updates on sales or revenues reported in this financial release. Achieve Life Sciences remains a late-stage specialty pharmaceutical company, navigating various risks related to clinical development, regulatory approval, and market conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.